Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.550-1.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.550. The company issued revenue guidance of $375 million-395 million, compared to the consensus revenue estimate of $389.96 million.
A number of analysts have recently weighed in on the company. TheStreet lowered Halozyme Therapeutics from a b rating to a c+ rating in a research note on Friday, May 14th. SVB Leerink began coverage on Halozyme Therapeutics in a research note on Monday, May 17th. They issued an outperform rating and a $56.00 price target for the company. Piper Sandler reaffirmed a neutral rating and issued a $48.00 price target (down previously from $50.00) on shares of Halozyme Therapeutics in a research note on Monday, May 17th. Finally, Zacks Investment Research lowered Halozyme Therapeutics from a hold rating to a sell rating and set a $46.00 price target for the company. in a research note on Tuesday, March 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $49.20.
HALO traded up $0.59 during trading on Friday, reaching $42.31. The stock had a trading volume of 11,457 shares, compared to its average volume of 1,246,621. The firm’s 50 day simple moving average is $44.34. The company has a quick ratio of 8.22, a current ratio of 8.77 and a debt-to-equity ratio of 11.61. The company has a market capitalization of $6.02 billion, a P/E ratio of 36.92 and a beta of 1.48. Halozyme Therapeutics has a one year low of $22.11 and a one year high of $56.40.
In related news, Director Kenneth J. Kelley sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, April 14th. The stock was sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the sale, the director now directly owns 179,833 shares in the company, valued at approximately $8,092,485. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael J. Labarre sold 28,689 shares of Halozyme Therapeutics stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $42.56, for a total value of $1,221,003.84. Insiders have sold 183,689 shares of company stock valued at $7,707,504 over the last 90 days. Corporate insiders own 2.60% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
See Also: How to Invest in an Index Fund
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.